Ipilimumab, an antibody-targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has yielded a CR rate of 42% in patients with post-aSCT relapsed AML [95]. This evidence concerns the gene CTLA4 and acute myeloid leukemia.